Related Experiment Video
Updated: May 15, 2026

Quantitative and Temporal Control of Oxygen Microenvironment at the Single Islet Level
Published on: November 17, 2013
The treatment effect of diazoxide on 44 patients with congenital hyperinsulinism
1National Key Discipline of Pediatrics, Capital Medical University, Ministry of Education, Endocrine and Genetic Metabolic Center, Beijing Children's Hospital Affiliated to Capital Medical University, Beijing 100045, China.
Objective:
To study the treatment effect and safety of diazoxide on patients with congenital hyperinsulinism (CHI).
Research Design And Methods:
A total of 44 patients who have been hospitalized to our hospital and used diazoxide as a trial after diagnosis of CHI were chosen as research subjects. The clinical data of the patients were analyzed, and the treatment effects and safety of diazoxide on CHI were evaluated.
Results:
In the 44 patients studied, the blood glucoses of 36 cases recovered to normal level after using diazoxide, indicating that the 36 patients respond to the treatment of diazoxide. Eight cases still showed severe hypoglycemia after using diazoxide for 10 days, which indicated that the eight patients were unresponsive to diazoxide treatment. Eighteen patients suffered the side effect of fluid retention, and 12 patients suffered transient gastrointestinal reactions.
Conclusion:
Diazoxide is a first-line treatment of CHI with high safety. Most of the patients with CHI were responsive to diazoxide treatment. Diazoxide should be used as a trial immediately after CHI diagnosis was made.
Related Concept Videos
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Dipeptidyl Peptidase 4 Inhibitors
Diabetes Insipidus I: Introduction
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Diabetes Mellitus: Type 2 and Gestational
